- Home
- CBIO vs NEWT Comparison
CBIO vs NEWT Comparison
Compare CBIO & NEWT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBIO
- NEWT
- Stock Information
- Founded
- CBIO 2003
- NEWT 1998
- Country
- CBIO United States
- NEWT United States
- Employees
- CBIO N/A
- NEWT N/A
- Industry
- CBIO
- NEWT Major Banks
- Sector
- CBIO
- NEWT Finance
- Exchange
- CBIO Nasdaq
- NEWT Nasdaq
- Market Cap
- CBIO 308.0M
- NEWT 294.8M
- IPO Year
- CBIO N/A
- NEWT N/A
- Fundamental
- Price
- CBIO $14.29
- NEWT $12.37
- Analyst Decision
- CBIO Strong Buy
- NEWT Hold
- Analyst Count
- CBIO 5
- NEWT 4
- Target Price
- CBIO $25.60
- NEWT $13.00
- AVG Volume (30 Days)
- CBIO 98.3K
- NEWT 188.9K
- Earning Date
- CBIO 07-31-2025
- NEWT 07-28-2025
- Dividend Yield
- CBIO N/A
- NEWT 6.14%
- EPS Growth
- CBIO N/A
- NEWT 21.23
- EPS
- CBIO N/A
- NEWT 2.01
- Revenue
- CBIO N/A
- NEWT $364,004,000.00
- Revenue This Year
- CBIO N/A
- NEWT N/A
- Revenue Next Year
- CBIO N/A
- NEWT $12.73
- P/E Ratio
- CBIO N/A
- NEWT $6.15
- Revenue Growth
- CBIO N/A
- NEWT 20.91
- 52 Week Low
- CBIO $10.83
- NEWT $9.12
- 52 Week High
- CBIO $21.40
- NEWT $15.49
- Technical
- Relative Strength Index (RSI)
- CBIO 52.92
- NEWT 61.20
- Support Level
- CBIO $13.50
- NEWT $12.16
- Resistance Level
- CBIO $16.00
- NEWT $12.48
- Average True Range (ATR)
- CBIO 0.79
- NEWT 0.27
- MACD
- CBIO 0.16
- NEWT 0.02
- Stochastic Oscillator
- CBIO 39.68
- NEWT 73.00
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.